Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Alberto Sulli¹, Federica Goegan ², Emanuele Gotelli ², Massimo Patane' ³, Carmen Pizzorni ³, Sabrina Paolino ³, Elisa Alessandri ⁴ and Barbara Ruaro ⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…
Abstract Number: 1730 • 2018 ACR/ARHP Annual Meeting
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Silvia Pérez Esteban¹, Esperanza Naredo Sánchez¹, Sheila Recuero Díaz¹, Fredeswinda I. Romero-Bueno², Gabriel Herrero-Beaumont³ and Olga Sanchez-Pernaute⁴, ¹Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ²Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: Small vessel arteriopathy precedes the development of organ damage and tissue fibrosis in systemic sclerosis (SSc) and related disorders. It is currently considered that…
Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Oliver Distler¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer AG, Berlin, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
Abstract Number: 2692 • 2018 ACR/ARHP Annual Meeting
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
Victoria Flower^1,2, Shaney Barratt^3,4, Darren Hart⁵, Amanda MacKenzie², Jacqueline Shipley⁵, Stephen Ward² and John Pauling^1,2, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom, ²Centre for Therapeutic Innovations & Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Clinical Measurement Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, United Kingdom
Background/Purpose: Structural and functional vascular abnormalities occur in Systemic Sclerosis (SSc). We report on the use of High Frequency Ultrasound (HFUS) with Superb Microvascular Imaging…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Alberto Sulli¹, Maurizio Cutolo², Carmen Pizzorni², Sabrina Paolino², Elisa Alessandri², Emanuele Gotelli² and Barbara Ruaro², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…
Abstract Number: 745 • 2017 ACR/ARHP Annual Meeting
An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
John D. Pauling^1,2, Robyn T. Domsic³, Lesley Ann Saketkoo⁴, Celia Almeida⁵, Tracy M. Frech⁶, Francesca Ingegnoli⁷, Jane Withey⁸, Hilary Jay⁸, Emma Dures⁹, Joanna Robson¹⁰, Neil J. McHugh^11,12, Ariane L. Herrick^13,14, Marco Matucci-Cerinic¹⁵, Dinesh Khanna¹⁶ and Sarah Hewlett¹⁷, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Tulane, New Orleans, LA, ⁵HAS - Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Dept. of clinical and community science, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, ⁸Patient Research Partner, Bath, United Kingdom, ⁹Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, ¹⁰Rheumatology, University of the West of England (UWE Bristol), Bristol, United Kingdom, ¹¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ¹³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ¹⁴School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹⁵Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ¹⁶Department of Medicine, University of Michigan Scleroderma Program, Ann Arbor, MI, ¹⁷UWE Academic Rheumatology, University of West of England, Bristol, United Kingdom
Background/Purpose: Raynaud’s phenomenon (RP) is consistently ranked highest in patient surveys exploring the frequency and impact of disease related manifestations of systemic sclerosis (SSc). SSc-RP…
Abstract Number: 1686 • 2017 ACR/ARHP Annual Meeting
Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Dinesh Khanna¹, Lorele Mendez², Rajaie Namas³, Mary Ellen Csuka⁴, Paul Caldron⁵, Jerry A. Molitor⁶, Alan J. Kivitz⁷, Philip Waller⁸, Lee Shapiro⁹, Sabeen Najam¹⁰, Amber Khan¹¹, Virginia D. Steen¹², Aneureka Chadha¹³ and James R Seibold¹⁴, ¹University of Michigan, Ann Arbor, MI, ²Medical Research Center of Miami, Miami, FL, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁵Arizona Arthritis & Rheumatology Research PLLC, Phoenix, AZ, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Accurate Clinical Research Inc, Houston, TX, ⁹Rheumatology, Albany Medical College, Albany, NY, ¹⁰Accurate Clinical Management LLC, Baytown, TX, ¹¹Accurate Clinical Management LLC, Houston, TX, ¹²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹³Austin Regional Clinic, Austin, TX, ¹⁴Scleroderma Research Consultants LLC, Litchfield, CT
Background/Purpose: A topical therapy for either prevention or palliation of attacks would offer unique advantages to selected patients with Raynaud phenomenon (RP). This study used…
Abstract Number: 1700 • 2017 ACR/ARHP Annual Meeting
Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of…
Abstract Number: 1704 • 2017 ACR/ARHP Annual Meeting
Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Tomonori Ishii¹, Yasushi Kawaguchi², osamu ishikawa³, naruhiko takasaawa⁴, takao kodera⁵, hidekata yasuoka⁶, yuichi takahashi⁷, osamu takai⁸, Izaya Nakaya⁹, Hiroshi Fujii¹⁰, Yukiko Kamogawa¹⁰, Yuko Shirota¹⁰, Tsuyoshi Shirai¹⁰, Yoko Fujita¹¹, shinichiro saito¹², Hiroaki Shimokawa¹³ and Hideo Harigae¹⁰, ¹Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Dermatology, Gunma University Graduate School of Medicine, gunma, Japan, ⁴Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sendai, Japan, ⁵Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ⁷Ｙｕ　Ｆａｍｉｌｙ　Ｃlinic, Sendai, Japan, ⁸Osaki Citizen Hospital, Sendai, Japan, ⁹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ¹⁰Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹¹Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan, ¹²IMS Meirikai Sendai General Hospital, Sendai, Japan, ¹³Department of Cardiovascular medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Patients with systemic sclerosis (SSc) often display Raynaud’s phenomenon, which causes digital skin ulcers. Since these ulcers are not associated with autoimmune factors, conventional…
Abstract Number: 2096 • 2017 ACR/ARHP Annual Meeting
Nailfold Capillaroscopy Is an Opportunity for Telerheumatology
Jacob R. Stever¹, Nicholas Lebedoff², Tracy M. Frech³, Lesley A. Saketkoo⁴ and Marcus Snow⁵, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Internal Medicine, University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Rheumatology, Tulane University School of Medicine, New Orleans, LA, ⁵Internal Medicine, University of Nebraska, Omaha, NE
Background/Purpose: The 2013 classification criteria for systemic sclerosis (SSc) provide 2 points (towards a 9 point diagnosis) for patients who have abnormal capillaroscopy. In the…
Abstract Number: 2168 • 2017 ACR/ARHP Annual Meeting
Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis
Eun Hye Park¹, Woo Chang Hwang², Eun Young Lee¹, Eun Bong Lee¹, Yeong Wook Song³ and Jin Kyun Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Statistics, Data Science for Knowledge Creation Research Center, Seoul National University, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Interstitial lung disease in patients with polymyositis (PM) and dermatomyositis (DM) is characterized by decrease in both lung compliance and pulmonary vascularity, leading to…
Abstract Number: 2697 • 2017 ACR/ARHP Annual Meeting
Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
Matylda Sierakowska¹, Stanislaw Sierakowski², Marzena Olesinska³, Marek Brzosko⁴, Piotr Leszczynski⁵, Katarzyna Pawlak-Bus⁵, Bogdan Batko⁶, Piotr Wiland⁷, Maria Majdan⁸, Malgorzata Bykowska-Sochacka⁹, Wojciech Romanowski¹⁰, Aleksandra Zon-Giebel¹¹, Slawomir Jeka¹² and Mwidimi Ndosi¹³, ¹Department of Integrated Medical Care, Medical University of Bialystok, Bialystok, Poland, ²Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Poland, Bialystok, Poland, ³Department of Connective Tissue Disease, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ⁴Department of Rheumatology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland, ⁵Department of Rheumatology and Rehabilitation, Medical University in Poznan, Poznan, Poland, ⁶Center of Rheumatology, J. Dietl Hospital in Krakow, Krakow, Poland, ⁷Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ⁸Department of Rheumatology and Connective Tissue Diseases, Medical University in Lublin, Lublin, Poland, ⁹Dr J. Titz-Kosko Regional Hospital for Rheumatic Diseases in Sopot, Sopot, Poland, ¹⁰Poznan Centre of Rheumatology in Srem, Srem, Poland, ¹¹Silesian Center of Rheumatology, Rehabilitation and Prevention of Disability, Ustron, Poland, ¹²2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ¹³Department of Nursing and Midwifery, University of the West of England, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a chronic rheumatic disease that disturbs the patients’ biological, social, emotional spiritual, and physical functioning; resulting in reduced quality of…
Abstract Number: 164 • 2016 ACR/ARHP Annual Meeting
99mtc-Hdp Digital Blood Flow Scintigraphy for Assessment of Raynaud Phenomenon Associated with Hand-Arm Vibration Syndrome
Kyung-Ann Lee¹, Hyun-Woo Jeong², Sang Heon Lee³ and Hae-Rim Kim⁴, ¹Devision of rheumatology, Department of internal medicine, Konkuk University Medical center, Seoul, Korea, The Republic of, ²Department of Nuclear medicine, Konkuk University Medical center, Seoul, Korea, The Republic of, ³Department of Internal Medicine,Division of Rheumatology., Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea, The Republic of
Background/Purpose: This study aimed to analyze the 99mTc-HDP scintigraphic features in hand-arm vibration syndrome (HAVS) and to compare with primary Raynaud’s phenomenon (RP) and secondary…
Abstract Number: 842 • 2016 ACR/ARHP Annual Meeting
Aminaphtone Treatment Increases Skin Blood Perfusion and Related Clinical Symptoms in Patients Affected By Raynaud’s Phenomenon: A Pilot Study Based on Laser Speckle Contrast Analysis
Barbara Ruaro, Sabrina Paolino, Carmen Pizzorni, Maurizio Cutolo and Alberto Sulli, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy
Background/Purpose: Aminaphtone is an oral vasoactive drug used to treat microvascular impairement since 30 years, and recently suggested to down-regulate endothelin-1 production by endothelial cells,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].